Drugs / ACD856
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05783830 | Jan → Apr 2020 | Alzheimer disease | AlzeCure Pharma | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05077501 | Sep 2021 → May 2022 | Alzheimer disease | AlzeCure Pharma | Completed | No outcome recorded |
| Phase 1 | NCT05077631 | Feb 2021 → Feb 2022 | Alzheimer disease | AlzeCure Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACD856 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05077501 ↗ |
| Route | Oral | “ACD856 will be administered orally.” NCT05077501 ↗ |